Past, present and future of newborn screening in Chile

被引:20
|
作者
Cornejo, V. [1 ,2 ]
Raimann, E. [2 ]
Cabello, J. F. [2 ,3 ]
Valiente, A. [2 ]
Becerra, C. [4 ,5 ]
Opazo, M. [6 ]
Colombo, M. [3 ]
机构
[1] Univ Chile, Inst Nutr & Tecnol Alimentos INTA, Lab Genet Enfermedades Metabol, Santiago 7810000, Chile
[2] Univ Chile, Inst Nutr & Food Technol INTA, Lab Genet & Metab Dis, Santiago, Chile
[3] Hosp Carlos Buren, Lab Metab Dis, Valparaiso, Chile
[4] Minist Hlth Chile, Program Child Hlth, Santiago, Chile
[5] Minist Hlth Chile, Dept Publ Hlth Policy, Santiago, Chile
[6] Reg Clin Hosp Concepcion, Clin Lab Med Specialties, Concepcion, Chile
关键词
TANDEM MASS-SPECTROMETRY; FOLLOW-UP;
D O I
10.1007/s10545-010-9165-8
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
The history of the Newborn Screening Program in Chile begins in 1984, when a pilot plan was developed that demonstrated the feasibility of its implementation. In 1992, the Ministry of Health started a national newborn screening program for phenylketonuria (PKU) and congenital hypothyroidism (CH), and in 1998, this was extended to the entire country. Throughout this period, a total of 2,478,123 newborns (NB) have been analyzed, obtaining initial coverage of 48.8%, which was later increased to 87.7%, and at present it is at 98.7% of all NB of our country. During this period, 131 cases with PKU have been diagnosed, resulting in an incidence of 1:18,916 NB, an average age of diagnosis of 18 +/- 10.2 days and average phenylalanine level of 19,9 +/- 8.8 mg/dl. In relation to CH, 783 cases have been confirmed, arriving at an incidence of 1:3,163 NB, with average age of diagnosis of 12.5 +/- 6.9 days. Due to the good results of the program, the government is evaluating the initiation of an extended pilot program, to introduce other pathologies.
引用
收藏
页码:S301 / S306
页数:6
相关论文
共 50 条
  • [31] CKD Screening and Surveillance in Australia: Past, Present, and Future
    Venuthurupalli, K.
    Hoy, Wendy E.
    Healy, Helen G.
    Cameron, Anne
    Fassett, Robert G.
    [J]. KIDNEY INTERNATIONAL REPORTS, 2018, 3 (01): : 36 - 46
  • [32] Prenatal screening for cystic fibrosis: past, present and future
    Richards, CS
    Grody, WW
    [J]. EXPERT REVIEW OF MOLECULAR DIAGNOSTICS, 2004, 4 (01) : 49 - 62
  • [33] Progress in colorectal cancer screening: Past, present, and future
    Gray, Darrell M., II
    [J]. CANCER EPIDEMIOLOGY BIOMARKERS & PREVENTION, 2020, 29 (06)
  • [34] Cervical Cancer Screening-Past, Present, and Future
    Wentzensen, Nicolas
    Clarke, Megan A.
    [J]. CANCER EPIDEMIOLOGY BIOMARKERS & PREVENTION, 2021, 30 (03) : 432 - 434
  • [35] Lung cancer screening at the VA: Past, present and future
    Maurice, Nicholas M.
    Tanner, Nichole T.
    [J]. SEMINARS IN ONCOLOGY, 2022, 49 (3-4) : 206 - 212
  • [36] Pulmonary nodules and CT screening: the past, present and future
    Ruparel, M.
    Quaife, S. L.
    Navani, N.
    Wardle, J.
    Janes, S. M.
    Baldwin, D. R.
    [J]. THORAX, 2016, 71 (04) : 367 - 375
  • [37] Biomarkers in prostate cancer surveillance and screening: past, present, and futureBiomarkers in prostate cancer surveillance and screening: past, present, and future
    Cary, K. Clint
    Cooperberg, Mathew R.
    [J]. THERAPEUTIC ADVANCES IN UROLOGY, 2013, 5 (06) : 318 - 329
  • [38] UNIVERSITY OF CHILE - PAST AND PRESENT
    BRETON, BM
    [J]. MEDICINA-BUENOS AIRES, 1978, 38 (05) : 587 - 592
  • [39] Informed consent for expanded carrier screening: Past, present, and future
    Rink, Britton D.
    [J]. PRENATAL DIAGNOSIS, 2023, 43 (04) : 489 - 495
  • [40] Phenotypic screening in cancer drug discovery — past, present and future
    John G. Moffat
    Joachim Rudolph
    David Bailey
    [J]. Nature Reviews Drug Discovery, 2014, 13 : 588 - 602